These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 11900253)

  • 1. Rescuing the function of mutant p53.
    Bullock AN; Fersht AR
    Nat Rev Cancer; 2001 Oct; 1(1):68-76. PubMed ID: 11900253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.
    Rippin TM; Bykov VJ; Freund SM; Selivanova G; Wiman KG; Fersht AR
    Oncogene; 2002 Mar; 21(14):2119-29. PubMed ID: 11948395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53--a natural cancer killer: structural insights and therapeutic concepts.
    Römer L; Klein C; Dehner A; Kessler H; Buchner J
    Angew Chem Int Ed Engl; 2006 Oct; 45(39):6440-60. PubMed ID: 16983711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
    Brazda V; Muller P; Brozkova K; Vojtesek B
    Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
    Selivanova G; Wiman KG
    Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy.
    Wiman KG
    Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relevance of p53 protein and its mutations for novel strategies in cancer therapy].
    Müller P; Nenutil R; Vojtĕsek B
    Cas Lek Cesk; 2004; 143(5):313-7. PubMed ID: 15305766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of the transcription factor p53 in keratinocyte carcinomas.
    Brash DE
    Br J Dermatol; 2006 May; 154 Suppl 1():8-10. PubMed ID: 16712710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells.
    Donninger H; Binder A; Bohm L; Parker MI
    Biol Chem; 2008 Jan; 389(1):57-67. PubMed ID: 18095870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
    Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
    Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic mutation of the p53 gene derived from head and neck cancer prevents cells from undergoing apoptosis after DNA damage.
    Kawamata H; Omotehara F; Nakashiro K; Uchida D; Shinagawa Y; Tachibana M; Imai Y; Fujimori T
    Int J Oncol; 2007 May; 30(5):1089-97. PubMed ID: 17390010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis.
    Ho CK; Li G
    Br J Dermatol; 2005 Nov; 153(5):900-10. PubMed ID: 16225598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells.
    Chen D; Yu Z; Zhu Z; Lopez CD
    Cancer Res; 2006 Apr; 66(7):3485-94. PubMed ID: 16585172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting p53 for enhanced radio- and chemo-sensitivity.
    Lu C; El-Deiry WS
    Apoptosis; 2009 Apr; 14(4):597-606. PubMed ID: 19259822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative assessment of the functional p53 status in glioma cells.
    Kim EL; Yoshizato K; Kluwe L; Meissner H; Warnecke G; Zapf S; Westphal M; Deppert W; Giese A
    Anticancer Res; 2005; 25(1A):213-24. PubMed ID: 15816541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.
    Zalcenstein A; Stambolsky P; Weisz L; Müller M; Wallach D; Goncharov TM; Krammer PH; Rotter V; Oren M
    Oncogene; 2003 Aug; 22(36):5667-76. PubMed ID: 12944915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.